Want to see BJDX full AI Analyst Report?
Top Page
Bluejay Diagnostics
(NASDAQ:BJDX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▲(130.77% Upside)
Action:Reiterated
Date:04/08/26
The score is held down primarily by very weak financial performance (minimal revenue, ongoing losses, and persistent cash burn). Technicals add a mildly negative signal given the stock remains below key longer-term moving averages with negative MACD. Corporate events are a modest positive due to clinical and manufacturing progress, but they do not offset the current loss-making profile and funding/dilution overhang; valuation also offers limited support given negative earnings and no dividend.
Positive Factors
Pivotal SYMON‑II enrollment nearing completion
Near-complete pivotal enrollment materially shortens the regulatory pathway timeline and reduces clinical execution risk. Successful completion enables analysis to support a 510(k), strengthening the firm’s ability to commercialize a rapid IL-6 sepsis diagnostic and convert R&D investment into a marketable product.
Negative Factors
Persistent negative cash flow
Sustained multi‑million negative operating and free cash flow creates ongoing funding needs and heightens execution risk until revenue materializes. Even with some improvement, persistent burn compels dilution or external financing, limiting ability to invest opportunistically in commercialization or scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal SYMON‑II enrollment nearing completion
Near-complete pivotal enrollment materially shortens the regulatory pathway timeline and reduces clinical execution risk. Successful completion enables analysis to support a 510(k), strengthening the firm’s ability to commercialize a rapid IL-6 sepsis diagnostic and convert R&D investment into a marketable product.
Read all positive factors
Bluejay Diagnostics (BJDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$889.86K
Dividend YieldN/A
Average Volume (3M)5.27M
Price to Earnings (P/E)―
Beta (1Y)-0.58
Revenue GrowthN/A
EPS Growth98.81%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,034,715
10 Day Avg. Volume15,571,172
30 Day Avg. Volume5,266,425
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bluejay Diagnostics Business Overview & Revenue Model
Company Description
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orches...
How the Company Makes Money
null...
Bluejay Diagnostics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 249.04K | 0.00 |
| Gross Profit | -98.37K | 0.00 | -199.10K | -780.96K | 48.91K | 0.00 |
| EBITDA | -6.73M | -6.68M | -6.70M | -9.17M | -8.99M | -2.98M |
| Net Income | -6.90M | -6.85M | -7.72M | -9.95M | -9.30M | -3.73M |
Balance Sheet | ||||||
| Total Assets | 5.60M | 7.12M | 6.66M | 4.87M | 13.52M | 21.02M |
| Cash, Cash Equivalents and Short-Term Investments | 3.68M | 5.16M | 4.30M | 2.21M | 10.11M | 19.05M |
| Total Debt | 100.52K | 120.21K | 222.25K | 352.98K | 492.62K | 0.00 |
| Total Liabilities | 1.42M | 1.14M | 927.92K | 1.97M | 1.98M | 637.16K |
| Stockholders Equity | 4.18M | 5.98M | 5.73M | 2.89M | 11.54M | 20.38M |
Cash Flow | ||||||
| Free Cash Flow | -6.65M | -6.23M | -8.13M | -9.02M | -8.94M | -4.39M |
| Operating Cash Flow | -6.46M | -6.05M | -7.82M | -8.31M | -7.74M | -4.37M |
| Investing Cash Flow | -189.05K | -173.74K | -306.78K | -704.17K | -1.20M | -23.95K |
| Financing Cash Flow | 7.22M | 7.09M | 10.22M | 1.11M | 8.07K | 22.53M |
Bluejay Diagnostics Technical Analysis
Neutral
0.65
Price Trends
2.39
Negative
2.14
Negative
3.17
Negative
Market Momentum
-0.30
Negative
42.30
Neutral
44.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Neutral. The current price of 0.65 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 2.39, and below the 200-day MA of 3.17, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 42.30 is Neutral, neither overbought nor oversold. The STOCH value of 44.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BJDX.
Bluejay Diagnostics Risk Analysis
Bluejay Diagnostics disclosed 58 risk factors in its most recent earnings report. Bluejay Diagnostics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bluejay Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
BJDX
Bluejay Diagnostics
1.15
-4.73
-80.44%
AEMD
Aethlon Medical
3.02
-63.98
-95.49%
BBLG
Bone Biologics
0.92
-1.62
-63.82%
DHAI
DIH Holdings US, Inc Class A
0.02
-6.92
-99.71%
Bluejay Diagnostics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study
Positive
Jul 22, 2026
On July 21, 2026, Bluejay Diagnostics announced it had completed patient enrollment in its SYMON-II multicenter clinical validation study ahead of schedule, reaching the target of 750 intensive-care sepsis patients. Conducted across leading U.S. i...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility
Positive
Jun 9, 2026
At its June 9, 2026 annual meeting, Bluejay Diagnostics shareholders re-elected all incumbent directors and ratified Wolf Company, P.C. as the independent auditor for the 2026 fiscal year, with quorum achieved from 414,092 of 1,034,715 eligible s...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Bluejay Diagnostics Completes Private Placement to Extend Runway
Positive
Jun 8, 2026
On June 2, 2026, Bluejay Diagnostics entered into securities purchase and registration rights agreements with institutional and accredited investors for a private placement of pre-funded warrants and Series G and H warrants tied to 3,655,917 share...
Business Operations and Strategy
Bluejay Diagnostics Forms U.S. Manufacturing Partnership for Symphony
Positive
Jun 2, 2026
On May 27, 2026, Bluejay Diagnostics entered an agreement with Argonaut Manufacturing Services for a suite of manufacturing services to support its Symphony platform and IL-6 testing products. The deal covers planning, engineering, supply chain ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.